Recon: FTC warns drugmakers over ‘junk’ Orange Book patents; FDA solicits public feedback on advisory committee reforms
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States